Easier treatment schedule for multiple myeloma falls flat before it starts
NCT ID NCT06348147
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to test a less intense version of a standard four-drug combination (Dara-RVd) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal was to see if giving one drug (bortezomib) once a week instead of twice could still work well while causing fewer side effects like nerve damage. However, the trial was withdrawn before any participants were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVd)
What this could lead to
If successful, this could show that a less frequent dosing schedule works as well as the standard, making treatment more convenient and reducing nerve damage risk.
What could go wrong
This trial was withdrawn before enrolling any participants, so no data was collected. The approach remains unproven, and the standard schedule is still the only evidence-based option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27516, United States